One hundred and forty-four patients with symptomatic benign prostatic hyperplasia were treated by transurethral microwave thermotherapy between January and December 1991. Before entering the study, all patients had a Boyarsky symptom score greater-than-or-equal-to 8, peak flow rate less-than-or-equal-to 15 ml/s and postvoiding residual urine less-than-or-equal-to 200 ml. Transurethral thermotherapy with the Prostatron (Technomed) was carried out as a single session (60 min) without any analgesia or sedation. Acute urinary retention occurred in 19.4% of the patients after treatment requiring catheterization for 2-3 weeks; morbidity rate was 5.5%. Six months after treatment, Boyarsky symptom score decreased from 11.73 +/- 4.97 to 4.40 +/- 3.21 (mean values +/- SD); peak flow rate increased on average from 8.97 +/- 4.18 to 13.07 +/- 4.87 ml/s and postvoiding residual urine decreased from 135 +/- 17.9 to 63 +/- 34.7 ml. Slight further improvement was shown, in a few patients, at the 1-year follow-up visit.
TRANSURETHRAL MICROWAVE THERMOTHERAPY IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA / Tubaro, A., G. P., P.G., Trucchi, A., A., B., Stoppacciaro, A., E., T., R., B.P., A., F., C., L., R., A.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 23:2(1993), pp. 285-291.
TRANSURETHRAL MICROWAVE THERMOTHERAPY IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
TUBARO, ANDREA;TRUCCHI, Alberto;STOPPACCIARO, ANTONELLA;
1993
Abstract
One hundred and forty-four patients with symptomatic benign prostatic hyperplasia were treated by transurethral microwave thermotherapy between January and December 1991. Before entering the study, all patients had a Boyarsky symptom score greater-than-or-equal-to 8, peak flow rate less-than-or-equal-to 15 ml/s and postvoiding residual urine less-than-or-equal-to 200 ml. Transurethral thermotherapy with the Prostatron (Technomed) was carried out as a single session (60 min) without any analgesia or sedation. Acute urinary retention occurred in 19.4% of the patients after treatment requiring catheterization for 2-3 weeks; morbidity rate was 5.5%. Six months after treatment, Boyarsky symptom score decreased from 11.73 +/- 4.97 to 4.40 +/- 3.21 (mean values +/- SD); peak flow rate increased on average from 8.97 +/- 4.18 to 13.07 +/- 4.87 ml/s and postvoiding residual urine decreased from 135 +/- 17.9 to 63 +/- 34.7 ml. Slight further improvement was shown, in a few patients, at the 1-year follow-up visit.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
